STAAR Surgical (NASDAQ:STAA) is a company that specializes in the development, manufacture, and marketing of implantable lenses for the eye. These lenses are used in refractive surgery to improve vision. STAAR Surgical competes with other companies in the ophthalmic industry, such as Alcon and Bausch + Lomb.
On December 9, 2025, John Young from Canaccord Genuity set a price target of $30.75 for STAA. At that time, the stock was priced at $25.89, suggesting a potential increase of about 18.77%. This target reflects a positive outlook for the company's future performance.
The stock has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects. The Zacks rating system emphasizes the importance of earnings estimates, which are key drivers of stock prices. This upgrade suggests that STAA may see upward movement soon.
Currently, STAA is priced at $25.59, showing an increase of 8.71% or $2.05. During the trading day, the stock fluctuated between a low of $25.09 and a high of $27.50. Over the past year, it has reached a high of $30.81 and a low of $13.50.
STAA has a market capitalization of approximately $1.27 billion, indicating its size in the market. The trading volume for the day is 5.54 million shares, reflecting investor interest. The company's positive outlook and recent upgrades make it an attractive option for investors.
